Retina 2012™

Program Overview
  Vitreoretinal specialists are faced with varying challenges, including the implementation of new diagnostic and treatment modalities. The goal of this exciting and fast-paced course is to present the most recent advances in the field, while exploring methods of their rational integration into everyday clinical practice.

A renowned faculty has been selected to present this information in both formal lectures and informal discussions. In a relaxed setting, faculty and attendees will discuss specific cases, new therapy and imaging techniques and the latest surgical strategies.		  
     
 

Learn how to apply new diagnostic and treatment
modalities to your practice

  
 
Learning Objectives  
At the conclusion of this activity, attendees should be able to:  
  • Explain how tapply spectral domain-OCT in the management of macular diseases.
  • Summarize current applications of fundus autoflurescence, ultrawidefield angiography, and confocal microscopy.
  • Analyze the best clinical decision-making strategies for using anti-VEGF agents for treating wet macular degeneration.
  • Identify the implications of the CATT Trial for current management of wet AMD.
  • Define the role of high-affinity anti-VEGF agents in reducing treatment frequency in wet AMD treatment.
  • Discuss the evolving paradigm shift in the treatment of foveal-involved diabetic macular edema.
  • Apply evidence-based strategies for the optimal use of anti-VEGF agents, laser therapy, and intravitreal steroids in the management of diabetic retinopathy and retinal venous occlusive disease.
  • Describe the potential role of intravitreal agents for treatment of symptomatic vitreomacular adhesions and macular holes.
  • Discuss the use of genetic markers in managing choroidal melanoma.
  • Explain updated strategies for screening and treating retinopathy of prematurity, including new information about the primary use of anti-VEGF agents.
  • Apply the latest diagnostic and treatment techniques in the management of posterior segment inflammatory disorders.
  • Describe the most important new developments in vitreoretinal surgery, including the move tambulatory vitreoretinal surgery.
 
   

Register early and save!
 

   
 
This continuing medical education activity is jointly sponsored by
Held in conjunction with
  
Vindico Medical Education and
OCULAR SURGERY NEWS
Hawaiian Eye™ 2012
  

 
 

ACCREDITATION: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Ocular Surgery News® and Vindico Medical Education. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION:This live activity has been approved for AMA PRA Category 1 Credits™.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.